Schneider Pascal, Tenured Senior Lecturer and Researcher
Pascal Schneider studied biochemistry and obtained a PhD in 1992 at the University of Lausanne. He performed a post-doc with MAJ Ferguson at the University of Dundee, Scotland, and then joined the research group of J. Tschopp at the Department of Biochemistry, University of Lausanne, where he has been appointed assistant professor in 2002 and senior lecturer and researcher in 2006. Ligands and receptors of the TNF family are his major research interest.
FUNCTIONAL CHARACTERIZATION OF TNF FAMILY LIGANDS
TNF family ligands are trimeric, type II transmembrane proteins that can either function as membrane-bound proteins or as soluble cytokines after proteolytic processing. Although they are predominantly active in the development, homeostasis and function of the immune system, they are also involved in several other processes such as control of bone turnover, mammary gland development and morphogenesis of skin derivatives such as hair, teeth and sweat glands. Primary defects in TNF family ligands or their receptors are directly associated to several inherited diseases, whereas deregulated expression of some members is implicated in the onset and/or maintenance of autoimmune conditions or malignancies. The TNF/TNFR family thus provides a number of interesting therapeutic targets.
B cells are key components of the humoral immune response. Some B cell types in the peritoneal cavity or in the splenic marginal zone encode a relatively limited repertoire of antibodies that are mainly directed against carbohydrate epitopes. These B cells give rise to plasma cells secreting so called “natural antibodies” crucial to provide broad protection against bacterial infections. Other B cells in the spleen, lymph nodes and other secondary lymphoid organs can produce high affinity antibodies against more specific antigens such as microbial toxins. From B cell precursors in the bone marrow to fully differentiated antibody-secreting plasma cells homing in the bone marrow or sub-mucosal areas of lymphoid organs such as tonsils, B cells undergo a number of maturation and selection steps, achieved in part by the availability of sufficient amounts of specific survival factors. The TNF ligand BAFF, also known as BLyS, supports survival of newly formed B cells as they exit from the bone marrow. BAFF is also important a later stages to maintain the pool of mature B2 B cells and marginal zone B cells. Another TNF family ligand, APRIL, shares receptors with BAFF and is believed to help B cells at terminal stages of differentiation (Fig.1).
In a very different biological context, the TNF family ligand ectodysplasin A (EDA) participates in the development of skin appendages, such as teeth, hair, eccrine sweat glands and numerous other glands (Fig. 2). EDA-deficiency in human and various animal species such as mice and dogs causes one form of ectodermal dysplasia (X-linked hypohidrotic ectodermal dysplasia, XLHED). There is presently no cure for ectodermal dysplasia. This disease can be particularly dangerous for young, undiagnosed patients, decreases the quality of life, can have severe impacts on self-esteem, and generates important financial burden for palliative treatments. In the past, our group has demonstrated the feasibility to cure XLHED in very young mice and dogs by protein replacement therapy (with the collaboration of Dr M. Casal at the University of Pennsylvania for experiments performed in dogs) (Fig.3). Recently, we have given full support to the initiators of Edimer, a newly founded company whose goal is to launch clinical trials in XLHED patients by the end of 2011, and with whom we are associated from a research point of view.
BAFF and APRIL
TNF family ligands signal by engagement of one or several receptors of the TNF receptor family. Some TNF ligands, in addition to their cognate receptors, interact with unconventional partners such a proteoglycans. Most TNF family ligands assemble as homotrimers and display three receptor-binding sites. Recruitment of three receptors to the trimeric ligand is the first signaling step. In the past few years, several groups including our own have accumulated evidence that the form of ligand presented to responsive cells is very important. It is now generally considered that membrane-bound and soluble TNF family ligands, including TNF itself, can trigger distinct effects. Membrane-bound ligands may be presented in a dense manner, “cross-linked” by the membrane to which they are physically attached, allowing the recruitment of more than three receptors in close proximity. Depending on the receptor, this may or may not be required for the generation of an optimal intracellular signal. As an example, TNF-R1 signals in response to soluble TNF, whereas TNF-R2 requires membrane-bound TNF. We wondered whether this concept could be extended to various forms of soluble ligands. Indeed, soluble BAFF exists either as trimers (BAFF 3-mer), or as an ordered assembly of 20 trimers (BAFF 60-mer), whereas APRIL can interact with carbohydrate side chains of proteoglycans that may cross-link soluble trimeric APRIL (Fig. 1). We reasoned that the occurrence of BAFF and APRIL as trimers and higher order multimers might be functionally relevant, should they trigger receptors differently. BAFF binds to BAFF-R, TACI and BCMA, whereas APRIL binds TACI and BCMA. We indeed found that BAFF 3-mer and BAFF 60-mer could both signal through BAFFR, but that TACI (and BCMA) only responded to BAFF 60-mer and not to BAFF 3-mer. Similar observations were made with APRIL, which needed to be cross-linked in order to activate TACI. In other experiments, we have compared wild type mice, BAFF -/- mice and mice expressing membrane-bound BAFF only. When required, these mice were also provided with recombinant forms of BAFF 3-mer or BAFF 60-mer. Membrane-bound BAFF was unable to maintain the mature B cell pool, whereas soluble BAFF could. Membrane-bound BAFF (or BAFF 60-mer) was however required to induce specific B cell markers in the mature B cell pool. In collaboration with Dr B. Huard in Geneva, we also addressed the physiological relevance of APRIL-proteoglycan interaction in human. Proteoglycan-bound APRIL improved survival of primary human plasma cells ex vivo. Also, APRIL produced in small amounts by epithelial tonsil cells in a normal situation, and in greater amounts by neutrophils upon inflammation, accumulated on neighboring proteoglycans and correlated with the presence of numerous plasma cells. Proteoglycan-bound APRIL is therefore likely to provide a survival niche for plasma cells.
Of course, several questions remain to be addressed: what are the relative contributions of membrane-bound BAFF and BAFF 60-mer in vivo? Which of the different forms of BAFF and APRIL are to be found in vivo? Does their ratio change in pathological conditions? Are they all sensitive to BAFF-blocking drugs currently tested in clinical trials?
There are strong genetic evidences that EDA must be processed in a soluble form to exert its function (Fig. 2). EDA is unique in that is contains a collagen-like domain in addition to its receptor-binding domain. We have identified a proteoglycan-binding region in EDA that is distinct from both the receptor-binding domain and the collagen domain. Binding to proteoglycan restricts EDA’s distribution in vivo, although the physiological impact of this observation remains to be determined. The presence of the collagen domain was found to bring together two trimeric receptor-binding domains in the same molecule, resulting in a considerable increase of biological activity (Fig. 1).
As mentioned above, EDA-deficiency leads to XLHED. However, few case studies also reported EDA mutations in patients missing some teeth (selective tooth agenesis), with no or very little involvement of other ectodermal appendages. Dr G. Mues (Baylor College of Dentistry, Dallas) characterized a four-generation family affected with a non-syndromic tooth defect, in which all affected individuals displayed a V365A mutation in EDA. We characterized the biochemical effect of this and five further EDA mutations associated with tooth agenesis. EDA found in XLHED is totally inactive, whereas those found in tooth agenesis often have an impaired but not totally abrogated ability to bind EDAR. Those that bound EDAR normally were either produced at lower levels, or displayed impaired ability to signal in a biological assay. Thus, we propose that hypomorph EDA mutations produce teeth defects, with no major impact on other structures. Teeth may therefore require stronger or higher quality EDAR signals to form properly.
Future work on EDA and EDAR will assess whether agonist anti-EDAR antibodies can be produced, whether predictive markers of treatment efficacy can be identified, whether EDAR signaling has any impact in adults, and whether a successful treatment induces biomarkers that can be monitored.
- Nys J, Smulski CR, Tardivel A, Willen L, Kowalczyk C, Donzé O, Huard B, Hess H, Schneider P. No Evidence That Soluble TACI Induces Signalling via Membrane-Expressed BAFF and APRIL in Myeloid Cells. PLoS One. 2013 Apr 19;8(4):e61350. doi: 10.1371/journal.pone.0061350. Print 2013.
- Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C. Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast. Sci Transl Med. 2013 Apr 24;5(182):182ra55. doi: 10.1126/scitranslmed.3005654.
- Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemčovičová I, Wang EC, Stanton RJ, Macauley M, Norris P, Willen L, Ruckova E, Nomoto A, Schneider P, Hahn G, Zajonc DM, Ware CF, Wilkinson GW, Benedict CA. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe. 2013 Mar 13;13(3):324-35. doi: 10.1016/j.chom.2013.02.003.
- Kong M, Muñoz N, Valdivia A, Alvarez A, Herrera-Molina R, Cárdenas A, Schneider P, Burridge K, Quest AF, Leyton L. Thy-1-mediated cell-cell contact induces astrocyte migration through the engagement of αVβ3 integrin and syndecan-4. Biochim Biophys Acta. 2013 Jun;1833(6):1409-20. doi: 10.1016/j.bbamcr.2013.02.013. Epub 2013 Feb 26.
- Smulski CR, Beyrath J, Decossas M, Chekkat N, Wolff P, Estieu-Gionnet K, Guichard G, Speiser D, Schneider P, Fournel S. Cysteine-rich domain 1 of CD40 mediates receptor self-assembly. J Biol Chem. 2013 Apr 12;288(15):10914-22. doi: 10.1074/jbc.M112.427583. Epub 2013 Mar 5.
- Pellegrini M, Willen L, Perroud M, Krushinskie D, Strauch K, Cuervo H, Day ES, Schneider P, Zheng TS. Structure of the extracellular domains of human and Xenopus Fn14: implications in the evolution of TWEAK and Fn14 interactions. FEBS J. 2013 Apr;280(8):1818-29. doi: 10.1111/febs.12206. Epub 2013 Mar 18.
- Zhang N, Wang X, Huo Q, Li X, Wang H, Schneider P, Hu G, Yang Q. The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL in breast cancer. J Biol Chem. 2013 Feb 13. [Epub ahead of print]
- Schmiedel BJ, Nuebling T, Steinbacher J, Malinovska A, Wende CM, Azuma M, Schneider P, Grosse-Hovest L, Salih HR. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance. J Immunol. 2013 Jan 15;190(2):821-31. doi: 10.4049/jimmunol.1201792. Epub 2012 Dec 14.
- Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, Schneider P, Jung G, Grosse-Hovest L, Salih HR. RANKL Expression, Function, and Therapeutic Targeting in Multiple Myeloma and Chronic Lymphocytic Leukemia. Cancer Res. 2013 Jan 15;73(2):683-94. doi: 10.1158/0008-5472.CAN-12-2280. Epub 2012 Nov 8.
- Heinz LX, Rebsamen M, Rossi DC, Staehli F, Schroder K, Quadroni M, Gross O, Schneider P, Tschopp J. The death domain-containing protein Unc5CL is a novel MyD88-independent activator of the pro-inflammatory IRAK signaling cascade. Cell Death Differ. 2012 Apr;19(4):722-31. doi: 10.1038/cdd.2011.147. Epub 2011 Dec 9.
- Voutilainen M, Lindfors PH, Lefebvre S, Ahtiainen L, Fliniaux I, Rysti E, Murtoniemi M, Schneider P, Schmidt-Ullrich R, Mikkola ML. Ectodysplasin regulates hormone-independent mammary ductal morphogenesis via NF-κB. Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5744-9. doi: 10.1073/pnas.1110627109. Epub 2012 Mar 26.
- Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18384-9. doi: 10.1073/pnas.1209171109. Epub 2012 Oct 22.
- Herrera-Molina R, Frischknecht R, Maldonado H, Seidenbecher CI, Gundelfinger ED, Hetz C, Aylwin Mde L, Schneider P, Quest AF, Leyton L. Astrocytic αVβ3 integrin inhibits neurite outgrowth and promotes retraction of neuronal processes by clustering Thy-1. PLoS One. 2012;7(3):e34295. doi: 10.1371/journal.pone.0034295. Epub 2012 Mar 30.
- Lefebvre S, Fliniaux I, Schneider P, Mikkola ML. Identification of ectodysplasin target genes reveals the involvement of chemokines in hair development. J Invest Dermatol. 2012 Apr;132(4):1094-102. doi: 10.1038/jid.2011.453. Epub 2012 Jan 26.
- Kimberley FC, van der Sloot AM, Guadagnoli M, Cameron K, Schneider P, Marquart JA, Versloot M, Serrano L, Medema JP. The design and characterization of receptor-selective APRIL variants. J Biol Chem. 2012 Oct 26;287(44):37434-46. doi: 10.1074/jbc.M112.406090. Epub 2012 Sep 7.
- Boeglin E, Smulski CR, Brun S, Milosevic S, Schneider P, Fournel S. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells. PLoS One. 2011;6(10):e25542. doi: 10.1371/journal.pone.0025542. Epub 2011 Oct 3.
- Ganeff C, Remouchamps C, Boutaffala L, Benezech C, Galopin G, Vandepaer S, Bouillenne F, Ormenese S, Chariot A, Schneider P, Caamaño J, Piette J, Dejardin E. Induction of the Alternative NF-κB pathway by lymphotoxin αβ (LTαβ) relies on internalization of LTβ receptor. Mol Cell Biol. 2011 Nov;31(21):4319-34. doi: 10.1128/MCB.05033-11. Epub 2011 Sep 6.
- Kowalczyk C, Dunkel N, Willen L, Casal ML, Mauldin EA, Gaide O, Tardivel A, Badic G, Etter AL, Favre M, Jefferson DM, Headon DJ, Demotz S, Schneider P. Molecular and therapeutic characterization of anti-ectodysplasin A receptor (EDAR) agonist monoclonal antibodies. J Biol Chem. 2011 Sep 2;286(35):30769-79. doi: 10.1074/jbc.M111.267997. Epub 2011 Jul 5.
- Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, Wille L, Schneider P, Wortham K, Burkly LC, Hsu YM, Joseph IB. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs. 2011 Jul-Aug;3(4):362-75. Epub 2011 Jul 1.
- Fuertes Marraco SA, Scott CL, Bouillet P, Ives A, Masina S, Vremec D, Jansen ES, O'Reilly LA, Schneider P, Fasel N, Shortman K, Strasser A, Acha-Orbea H. Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo. PLoS One. 2011;6(6):e20189. doi: 10.1371/journal.pone.0020189. Epub 2011 Jun 2.
- Henríquez M, Herrera-Molina R, Valdivia A, Alvarez A, Kong M, Muñoz N, Eisner V, Jaimovich E, Schneider P, Quest AF, Leyton L. ATP release due to Thy-1-integrin binding induces P2X7-mediated calcium entry required for focal adhesion formation. J Cell Sci. 2011 May 1;124(Pt 9):1581-8. doi: 10.1242/jcs.073171.
- Bacchelli C, Buckland KF, Buckridge S, Salzer U, Schneider P, Thrasher AJ, Gaspar HB. The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice. J Allergy Clin Immunol. 2011 May;127(5):1253-9.e13. doi: 10.1016/j.jaci.2011.02.037. Epub 2011 Mar 31.
- Turchinovich G, Vu TT, Frommer F, Kranich J, Schmid S, Alles M, Loubert JB, Goulet JP, Zimber-Strobl U, Schneider P, Bachl J, Pearson R, Crossley M, Agenès F, Kirberg J. Programming of marginal zone B-cell fate by basic Kruppel-like factor (BKLF/KLF3). Blood. 2011 Apr 7;117(14):3780-92. doi: 10.1182/blood-2010-09-308742. Epub 2011 Feb 4.
- Bossen C, Tardivel A, Willen L, Fletcher CA, Perroud M, Beermann F, Rolink AG, Scott ML, Mackay F, Schneider P. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol. 2011 Mar;41(3):787-97. doi: 10.1002/eji.201040591. Epub 2011 Feb 1.
- Mues G, Tardivel A, Willen L, Kapadia H, Seaman R, Frazier-Bowers S, Schneider P, D'Souza RN. Functional analysis of ectodysplasin-A mutations causing selective tooth agenesis. Eur J Hum Genet. 2010 Jan;18(1):19-25. doi: 10.1038/ejhg.2009.127.
- Narasimamurthy R, Geuking P, Ingold K, Willen L, Schneider P, Basler K. Structure-function analysis of Eiger, the Drosophila TNF homolog. Cell Res. 2009 Mar;19(3):392-4. doi: 10.1038/cr.2009.16.
- Swee LK, Ingold-Salamin K, Tardivel A, Willen L, Gaide O, Favre M, Demotz S, Mikkola M, Schneider P. Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. J Biol Chem. 2009 Oct 2;284(40):27567-76. doi: 10.1074/jbc.M109.042259. Epub 2009 Aug 5.
- Salzer U, Bacchelli C, Buckridge S, Pan-Hammarström Q, Jennings S, Lougaris V, Bergbreiter A, Hagena T, Birmelin J, Plebani A, Webster AD, Peter HH, Suez D, Chapel H, McLean-Tooke A, Spickett GP, Anover-Sombke S, Ochs HD, Urschel S, Belohradsky BH, Ugrinovic S, Kumararatne DS, Lawrence TC, Holm AM, Franco JL, Schulze I, Schneider P, Gertz EM, Schäffer AA, Hammarström L, Thrasher AJ, Gaspar HB, Grimbacher B. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood. 2009 Feb 26;113(9):1967-76. doi: 10.1182/blood-2008-02-141937. Epub 2008 Nov 3.
- Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009 Jul;9(7):491-502. doi: 10.1038/nri2572.
|Christine Quintas (Kowalczyk)||Ph.D student|
|Sonia Schüpbach||Postdoctoral fellow|
|Cristian Smulski||Postdoctoral fellow|
|Aubry Tardivel||Research Associate|
|Michele Vigolo||Ph.D student|
|Léa Zaffalon||Master student|